Anadrol and MK-2866 Interaction: Avoid | Peptide Database

Join others researching Oxandrolone — share findings, ask questions, and learn from real experiences Oxandrolone is a synthetic oral anabolic-androgenic steroid derived from dihydrotestosterone (DHT), first synthesized in 1962 by Raphael Pappo at Searle Laboratories and introduced to the market in 1964 under the brand name Anavar. It was designed to be a mild anabolic agent with minimal androgenic activity, achieved through a structural modification where an oxygen atom replaces the carbon-2 atom in the A-ring of the DHT backbone. This modification significantly reduces androgenic potency while preserving anabolic effects on skeletal muscle. Oxandrolone is FDA-approved for the promotion of weight regain following involuntary weight loss due to surgery, chronic infection, severe trauma, and prolonged corticosteroid use, and for the relief of bone pain associated with osteoporosis. It has been extensively studied in burn recovery, HIV/AIDS-related wasting, and pediatric growth disorders. Among oral anabolic steroids, oxandrolone is considered one of the mildest with respect to hepatotoxicity and virilizing side effects, which has made it one of the few anabolic steroids used in women and children in clinical settings. Oxandrolone exerts its anabolic effects primarily through binding to the intracellular androgen receptor (AR), promoting nitrogen retention and protein synthesis in skeletal muscle tissue. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, which means it does not cause estrogen-mediated water retention or gynecomastia. The 2-oxo modification in the A-ring reduces its affinity for 5-alpha reductase, limiting conversion to more potent androgens in peripheral tissues and contributing to its relatively low androgenic profile. Oxandrolone increases protein synthesis through direct AR-mediated gene transcription, enhances the expression of genes involved in muscle hypertrophy and repair, and promotes collagen synthesis. It has also been shown to reduce cortisol-binding globulin levels and attenuate the catabolic effects of glucocorticoids, which is particularly relevant in burn patients and those recovering from severe trauma. Additionally, oxandrolone stimulates hepatic production of sex hormone-binding globulin (SHBG) to a lesser degree than other oral steroids, though it does suppress endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis.

Join others researching Trazodone — share findings, ask questions, and learn from real experiences Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that was originally approved by the FDA in 1981 for the treatment of major depressive disorder. However, its clinical use has shifted dramatically over the decades. Today, trazodone is prescribed almost exclusively at low doses as a sleep aid rather than as an antidepressant, making it one of the most commonly prescribed medications for insomnia in the United States. Its popularity stems from the fact that it is non-habit-forming, does not carry the dependence risk associated with benzodiazepines or Z-drugs, and can be used long-term without tolerance development. Trazodone has become particularly well-known in the bodybuilding and performance-enhancement community as a go-to solution for managing insomnia caused by trenbolone and other 19-nortestosterone derivatives, which are notorious for disrupting sleep architecture. Unlike many sleep medications, trazodone actually improves slow-wave sleep (deep sleep) rather than simply inducing sedation, which makes it especially valuable for recovery-focused athletes. Trazodone's sleep-promoting effects arise from a combination of pharmacological actions across multiple receptor systems. At low doses (25-100 mg), the dominant mechanism is potent antagonism of 5-HT2A serotonin receptors, which promotes slow-wave sleep and reduces sleep latency. Trazodone also blocks histamine H1 receptors, contributing to its sedative properties, and antagonizes alpha-1 adrenergic receptors, which produces additional drowsiness and accounts for the orthostatic hypotension sometimes observed. At higher doses used for depression (150-400 mg), serotonin reuptake inhibition (SRI) becomes more relevant, increasing serotonergic tone in a manner similar to SSRIs but with a distinct receptor profile. The compound is metabolized primarily by CYP3A4 to its active metabolite meta-chlorophenylpiperazine (mCPP), which has serotonin agonist properties. The dose-dependent shift in pharmacological profile explains why trazodone is sedating at low doses but can be activating or cause more typical serotonergic side effects at antidepressant doses.